Compare Amphastar Pharmaceuticals Inc (AMPH) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Starbucks Corp trades at $106.1 (market cap $120.82B). The key difference: Starbucks Corp is far larger — about 146.3× Amphastar Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.34% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SBUX | |
|---|---|---|
Market Cap | $826.08M | $120.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $106.82 |
52-Week Low | $16.87 | $78.46 |
Enterprise Value | $1.22B | $143.51B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Starbucks (SBUX) trades at $106.01, down 0.38% today, with a bullish technical signal and recent earnings beat in Q1 2026. The company's revenue grew to $37.18B in 2025, though net income margin compressed to 3.89%. Recent news highlights AI initiatives to cut software costs, while analyst consensus is split evenly between Buy and Hold ratings with a $107.67 price target.
Outlook remains mixed: AI cost savings and loyalty growth offer upside, but margin pressure and high P/E of 80.92 pose risks. Near-term performance hinges on Q2 2026 earnings versus the $0.65 EPS estimate and execution of operational efficiencies amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
